Geron Corporation (NASDAQ:GERN – Get Free Report) EVP Timothy Williams bought 12,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was purchased at an average price of $0.94 per share, for a total transaction of $11,280.00. Following the completion of the acquisition, the executive vice president owned 12,000 shares in the company, valued at $11,280. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Geron Stock Up 6.2%
Shares of NASDAQ GERN opened at $1.00 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 6.31 and a quick ratio of 4.61. The company has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.40. The stock has a market capitalization of $644.24 million, a P/E ratio of -12.50 and a beta of 0.62. Geron Corporation has a 1 year low of $0.84 and a 1 year high of $2.01.
Wall Street Analysts Forecast Growth
GERN has been the subject of several recent research reports. Weiss Ratings upgraded Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. Needham & Company LLC reduced their price objective on shares of Geron from $4.00 to $2.50 and set a “buy” rating for the company in a research report on Wednesday, October 28th. Finally, Wedbush dropped their target price on shares of Geron to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 28th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.75.
Check Out Our Latest Analysis on GERN
Hedge Funds Weigh In On Geron
Several hedge funds have recently made changes to their positions in GERN. Principal Financial Group Inc. boosted its stake in Geron by 20.5% in the 1st quarter. Principal Financial Group Inc. now owns 39,519 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 6,713 shares in the last quarter. Sei Investments Co. grew its holdings in shares of Geron by 23.0% during the first quarter. Sei Investments Co. now owns 41,891 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 7,840 shares during the last quarter. Nvest Financial LLC increased its position in shares of Geron by 1.7% in the 2nd quarter. Nvest Financial LLC now owns 517,150 shares of the biopharmaceutical company’s stock valued at $662,000 after acquiring an additional 8,676 shares during the period. GTS Securities LLC raised its stake in Geron by 71.6% in the 2nd quarter. GTS Securities LLC now owns 23,772 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 9,921 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Geron by 14.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 117,226 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 15,128 shares during the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.
Geron Company Profile
Geron Corporation is a biopharmaceutical company focused on developing and commercializing therapies for blood disorders and cancers. Its lead product, Rytelo (imetelstat), is a telomerase inhibitor approved in the United States to treat certain adults with lower-risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. Geron continues to develop imetelstat for potential use in other hematologic conditions. The company was founded in 1990 and is headquartered in Foster City, California.
Featured Stories
- Five stocks we like better than Geron
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.
